Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 3/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | TGM2 | P21980 | 10/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.37 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.36 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2892856 | 1.00 | USP2 (0.41) | USP2CYP3A4MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL2894392 | 0.91 | MAPT (0.40) | USP2CYP3A4MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL2896676 | 0.91 | MAPT (0.40) | USP2CYP3A4MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL1445653 | 0.91 | SMN1; SMN2 (0.44) | USP2CYP3A4MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL2458918 | 0.82 | TGM2 (0.42) | USP2CYP3A4MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL2888631 | 0.82 | TGM2 (0.42) | USP2CYP3A4MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL2458923 | 0.82 | TGM2 (0.42) | USP2CYP3A4MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL2891734 | 0.82 | TGM2 (0.42) | USP2CYP3A4MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL865337 | 0.82 | ALDH1A1 (0.47) | USP2CYP3A4MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL12564389 | 0.82 | SMN1; SMN2 (0.44) | SMN1; SMN2TGM2FOLH1PLA2G2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2083844-B1 | HCV NS3 PROTEASE INHIBITORS | MERCK SHARP & DOHME (US) | 2013-11-27 | — | — | EP | disclosed |
| US-8377874-B2 | HCV NS3 protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-02-19 | — | — | US | disclosed |
| US-8377874-B2 | HCV NS3 protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-02-19 | — | — | US | disclosed |
| US-8377874-B2 | HCV NS3 protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-02-19 | — | — | US | disclosed |
| US-20100286185-A1 | HCV NS3 Protease Inhibitors | MERCK SHARP & DOHME LLC | 2010-11-11 | — | — | US | disclosed |
| US-20100286185-A1 | HCV NS3 Protease Inhibitors | MERCK SHARP & DOHME LLC | 2010-11-11 | — | — | US | disclosed |
| US-20100286185-A1 | HCV NS3 Protease Inhibitors | MERCK SHARP & DOHME LLC | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286185-A1 | HCV NS3 Protease Inhibitors | HAVCR2, GTF3C3, CTSC | USP2 519/4885CYP3A4 154/4885MAPT 4330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.